Literature DB >> 17035604

Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.

Peter C Harris1, Kyongtae T Bae, Sandro Rossetti, Vicente E Torres, Jared J Grantham, Arlene B Chapman, Lisa M Guay-Woodford, Bernard F King, Louis H Wetzel, Deborah A Baumgarten, Philip J Kenney, Mark Consugar, Saulo Klahr, William M Bennett, Catherine M Meyers, Qin Jean Zhang, Paul A Thompson, Fang Zhu, J Philip Miller.   

Abstract

Data from serial renal magnetic resonance imaging of the Consortium of Radiologic Imaging Study of PKD (CRISP) autosomal dominant polycystic kidney disease (PKD) population showed that cystic expansion occurs at a consistent rate per individual, although it is heterogeneous in the population, and that larger kidneys are associated with more rapid disease progression. The significance of gene type to disease progression is analyzed in this study of the CRISP cohort. Gene type was determined in 183 families (219 cases); 156 (85.2%) had PKD1, and 27 (14.8%) had PKD2. PKD1 kidneys were significantly larger, but the rate of cystic growth (PKD1 5.68%/yr; PKD2 4.82%/yr) was not different (P = 0.24). Cyst number increased with age, and more cysts were detected in PKD1 kidneys (P < 0.0001). PKD1 is more severe because more cysts develop earlier, not because they grow faster, implicating the disease gene in cyst initiation but not expansion. These insights will inform the development of targeted therapies in autosomal dominant PKD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035604     DOI: 10.1681/ASN.2006080835

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  103 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

2.  High-resolution melt as a screening method in autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Grazia Maria Virzì; Alice Bruson; Valentina Corradi; Fiorella Gastaldon; Massimo de Cal; Marta Donà; Dinna N Cruz; Maurizio Clementi; Claudio Ronco
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

Review 3.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

Review 4.  Diagnosis and management of childhood polycystic kidney disease.

Authors:  William E Sweeney; Ellis D Avner
Journal:  Pediatr Nephrol       Date:  2010-10-29       Impact factor: 3.714

Review 5.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 6.  Autosomal dominant polycystic kidney disease and transplantation.

Authors:  Mariusz Niemczyk; Stanisław Niemczyk; Leszek Paczek
Journal:  Ann Transplant       Date:  2009 Oct-Dec       Impact factor: 1.530

7.  Loss of polycystin-1 causes centrosome amplification and genomic instability.

Authors:  Lorenzo Battini; Salvador Macip; Elena Fedorova; Steven Dikman; Stefan Somlo; Cristina Montagna; G Luca Gusella
Journal:  Hum Mol Genet       Date:  2008-06-19       Impact factor: 6.150

Review 8.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

9.  Family history of renal disease severity predicts the mutated gene in ADPKD.

Authors:  Moumita Barua; Onur Cil; Andrew D Paterson; Kairon Wang; Ning He; Elizabeth Dicks; Patrick Parfrey; York Pei
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

10.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.